Non-metastatic Ewing's sarcoma: twenty years of experience suggests that surgery is a prime factor for successful multimodality therapy.

Givens, Stanley S.; Woo, Shiao Y.; Huang, Le; Rich, Tyvin A.; Maor, Moshe; Cangır, Ayten; Murray, John A.; Oswald, Mary Jane; Peters, Lester J.; Jaffe, Norman

doi:10.3892/ijo.14.6.1039

Cited by 9 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study by Palta et al [120] found similar results with hyperfractionated and accelerated radiation doses in RIA patients; the overall 5-year survival rate in 14 patients was 86%. Notably, radiotherapy in RIS patients had less impact than chemotherapy because of the patients' tolerance of the radiation dosage from their previous radiotherapy for their breast cancer [121,122]. A second course of radiotherapy raises concerns about toxicities such as rib fracture, pneumonitis, and soft-tissue necrosis.…”

Section: Role Of Radiotherapymentioning

confidence: 99%

“…FNA cannot be expected to provide definitive information about the histologic architecture of RIS nor can FNA provide adequate material for an immunohistochemical evaluation. Therefore, core needle or incisional biopsies are preferred: they provide accurate and satisfactory sampling [51, [99] 5c Case reports (n ϭ 2) Case report and literature review Velaj and DeLuca (1987) [4] 5c Radiographic review (n ϭ 1) Case report and literature review Olcina et al (2008) [11] 5c Case report (n ϭ 1) Case report and literature review Chahin et al (2001) [14] 5c Case report (n ϭ 1) Case report and literature review Pendlebury et al (1995) [17] 5c [78] 5c Case report (n ϭ 2) Case report and literature review Kunkel et al (2008) [57] 5c Case report (n ϭ 1) Case report and literature review Quadros et al (2006) [80] 5c Case report (n ϭ 1) Case report and literature review Kuten et al (1985) [87] 5c Case report (n ϭ 7) Case report and literature review Khan et al (2009) [88] 5c Case report (n ϭ 1) Case report and literature review Plotti et al (2006) [91] 5c Case report (n ϭ 1) Case report and literature review Brenin et al (1998) [86] 5c Case report (n ϭ 1) Case report and literature review Feigenberg et al (2002) [100] 5c Case report (n ϭ 3) Case report and literature review Schulz et al (2000) [121] 5c Case report (n ϭ 3) Case report and literature review Givens et al (1999) [122] 5c Clinical review (n ϭ 85) Analysis of prognostic factors for RIS Okuno and Edmonson (1998) [113] 5c Case reports (n ϭ 2) Case report and literature review Mano et al (2006) [102] 5c Case report (n ϭ 1) Case report and literature review Perez-Ruiz et al (2009) …”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Radiation-Induced Sarcoma of the Breast: A Systematic Review

et al. 2012

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Evaluate the level of evidence to inform decision making for the treatment radiation induced sarcoma of the breast.2. Explain diagnostic criteria for radiation-induced sarcoma.3. Describe the effectiveness of surgery, chemotherapy and radiation therapy for radiation induced sarcoma of the breast.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTIntroduction. Radiation-induced sarcoma (RIS) is a rare, aggressive malignancy. Breast cancer survivors treated with radiotherapy constitute a large fraction of RIS patients. To evaluate evidenced-based practices for RIS treatment, we performed a systematic review of the published English-language literature. Methods. We performed a systematic keyword search of PubMed for original research articles pertaining to RIS of the breast. We classified and evaluated the articles based on hierarchal levels of scientific evidence.Results. We identified 124 original articles available for analysis, which included 1,831 patients. No randomized controlled trials involving RIS patients were found. We

show abstract

Section: Role Of Radiotherapymentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

Radiation-Induced Sarcoma of the Breast: A Systematic Review

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Patients who are left with signi;icant amounts of viable tumor in the resected specimen following neoadjuvant chemotherapy that have less than wide surgical margins (14)(15)(16) . In this study, positive surgical margin(s) and larger tumor size (>10 cm) was accompanied by signi;icantly lower disease free and overall survival (p<0.005) (;igure 2) which is consistent with other studies.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy for Ewing sarcoma: A 5 year experience from Iran cancer institute

Esmati

Safaei

Babaei

et al. 2016

IJRR

View full text Add to dashboard Cite

Background: Ewing Sarcoma Family of Tumors (ESFTs) is the second most common primary tumors of bone in childhood. The decision regarding the op mal modality for achieving local tumor control remains uncertain. The aim of this study was to report the clinical features and outcome as well as reviewing risk factors in pa ents. Materials and Methods: This retrospec ve study included 75 ESFTs pa ents who were treated at cancer ins tute between 2004 and 2009. Files of all pa ents with ESFTs were reviewed retrospec vely and we called them for follow up. Specific data were collected with regard to the age at diagnosis, gender, tumor site and size, clinical stage, surgical procedure, plan of radiotherapy and treatment outcome (5-year and median survival). Results: The mean age at diagnosis was 21 that ranged from 1 to 52 years (SD = 9.6). The mean tumor size at diagnosis was 4.8±4.48 cm. The percent of biopsy only, par al and complete resec on was 54.7% (41 pa ents), 6.7% (5 pa ents) and 37.3% (28 pa ents) respec vely. Radiotherapy was done as defini ve treatment or postopera vely (adjuvant) in 46 (61.3%) and 16 (21.4%) pa ents respec vely. Overall 5 year survival was 24% and median survival for pa ents with and without metastases was 21±17 and 75±10 months. Conclusion: Presence of metastases, age at diagnosis, posi ve surgical margin and tumor size were the prognos c factors that influenced outcome of pa ents. This study suggests that radia on therapy is an acceptable local treatment modality in pa ents with Ewing sarcoma family.Keywords: Ew ing sarcom a, radiotherapy, m ultim odality treatm ent.

show abstract

“…[29][30][31] Use of markers in the specific diagnosis of disease have been considered, 32 but the most researched use of tumour markers has been in the development of prognostic risk groups in order to target therapy. [33][34][35][36][37][38] Use of tumour markers in the monitoring of patients following primary therapy has also been considered. 39,40 Rationale for a systematic review of tumour markers in paediatric oncology A persistent difficulty in conducting primary research in paediatric oncology, not just in relation to the use of tumour markers, is the relatively small number of children who develop disease, and the therefore low statistical power which individual primary studies have of detecting either treatment benefits or survival benefits arising out of prognostic staging (using tumour markers).…”

Section: Use Of Tumour Markers In Paediatric Oncologymentioning

confidence: 99%

mentioning

confidence: 99%

A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma

Riley

Burchill

Abrams

et al. 2003

Health Technol Assess

148

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents, York Publishing Services by:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS and public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please contact York Publishing Services at the address above. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to York Publishing Distribution and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.ncchta.org/htacd.htm). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma RD Riley NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent...

show abstract

Non-metastatic Ewing's sarcoma: twenty years of experience suggests that surgery is a prime factor for successful multimodality therapy.

Cited by 9 publications

References 0 publications

Radiation-Induced Sarcoma of the Breast: A Systematic Review

Radiation-Induced Sarcoma of the Breast: A Systematic Review

Radiotherapy for Ewing sarcoma: A 5 year experience from Iran cancer institute

A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma

Contact Info

Product

Resources

About